Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C66H86N18O12 |
Molecular Weight | 1323.5024 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(CC3=CC=CC=C3)C=N2)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@@H]8CCC(=O)N8
InChI
InChIKey=HHXHVIJIIXKSOE-QILQGKCVSA-N
InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB06788Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/vantas.html
Sources: http://www.drugbank.ca/drugs/DB06788
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/vantas.html
Histrelin is a gonadotropin releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant that delivers continuous therapeutic doses. Following an initial stimulatory phase with increased circulating levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient increase in concentration of gonadal steroids (testosterone and dihydrotestosterone in males), continuous administration of histrelin acetate results in decreased levels of LH and FSH due to a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1855 Sources: http://www.drugbank.ca/drugs/DB06788 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Vantas Approved UseVantas is indicated for the palliative treatment of advanced prostate cancer. Launch Date1.09745281E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16239357/ |
50 μg 1 times / day steady-state, subcutaneous implant dose: 50 μg route of administration: Subcutaneous implant experiment type: STEADY-STATE co-administered: |
HISTRELIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.398 ng × week/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16239357/ |
50 μg 1 times / day steady-state, subcutaneous implant dose: 50 μg route of administration: Subcutaneous implant experiment type: STEADY-STATE co-administered: |
HISTRELIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16239357/ |
50 μg 1 times / day steady-state, subcutaneous implant dose: 50 μg route of administration: Subcutaneous implant experiment type: STEADY-STATE co-administered: |
HISTRELIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.92 h |
500 μg single, subcutaneous dose: 500 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
HISTRELIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29.5% |
500 μg single, subcutaneous dose: 500 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
HISTRELIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
65 ug 1 times / day steady, subdermal Recommended Dose: 65 ug, 1 times / day Route: subdermal Route: steady Dose: 65 ug, 1 times / day Sources: Page: 14 |
unhealthy, children n = 47 Health Status: unhealthy Condition: central precocious puberty Age Group: children Sex: M+F Population Size: 47 Sources: Page: 14 |
Disc. AE: Implant site infection... AEs leading to discontinuation/dose reduction: Implant site infection (1 patient) Sources: Page: 14 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Implant site infection | 1 patient Disc. AE |
65 ug 1 times / day steady, subdermal Recommended Dose: 65 ug, 1 times / day Route: subdermal Route: steady Dose: 65 ug, 1 times / day Sources: Page: 14 |
unhealthy, children n = 47 Health Status: unhealthy Condition: central precocious puberty Age Group: children Sex: M+F Population Size: 47 Sources: Page: 14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/vantas.html
Curator's Comment: The implant is inserted subcutaneously in the inner aspect of the upper arm
The recommended dose of VANTAS is one implant for 12 months. Each implant contains 50 mg histrelin acetate to deliver 41 mg histrelin. The implant is inserted subcutaneously in the inner aspect of the upper arm and provides continuous release of histrelin (50 mcg/day) for 12 months of hormonal therapy. VANTAS should be removed after 12 months of therapy
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20814074
Histrelin at concentrations of 10(-7)M and 10(-8) M (a concentration of 10(-7) M was more effective than 10(-8) M), stimulated significantly VP secretion from isolated rat hypothalamo-neurohypophysial explants
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175654
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
WHO-VATC |
QL02AE05
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
FDA ORPHAN DRUG |
212605
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
NCI_THESAURUS |
C1910
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
FDA ORPHAN DRUG |
28488
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
WHO-ATC |
L02AE05
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
NDF-RT |
N0000175655
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
||
|
WHO-ATC |
H01CA03
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB06788
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
2975
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
CHEMBL1201255
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
DTXSID50227543
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
76712-82-8
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
3884
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
C029256
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
7657
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
W-105
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
SUB08046MIG
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
M6030
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | Merck Index | ||
|
H50H3S3W74
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
25077993
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
50975
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | RxNorm | ||
|
H50H3S3W74
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
C74270
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
HISTRELIN
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
5733
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY | |||
|
5739
Created by
admin on Fri Dec 16 18:25:52 UTC 2022 , Edited by admin on Fri Dec 16 18:25:52 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)